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Background: Reduced intensity conditioning (RI) regimens are
used as an alternative to traditional myeloablative conditioning
(MA) for allogeneic hematopoietic stem cell transplant (HSCT) in
children. The main rationale is to allow tumor kill while decreasing
the degree of acute toxicity due to conditioning regimen, which
could potentially also decrease the occurrence of late effects.
Objective: To examine growth parameters and prevalence of
chronic graft versus host disease (CGvHD) at specific timepoints
in pediatric survivors of RI HSCT as compared to matched controls
who received MA.
Design/Methods: Medical record review of all patients who re-
ceived a RI HSCT from 2000 to 5/2007 at a single institution, ex-
cluding patients who ever received .1 HSCT, survived\100 days
post RI HSCT or had a primary diagnosis that would affect growth
directly. Remaining patients were matched to MA recipients by age
at HSCT andmalignancy yes/no. It was not always possible tomatch
for HSC source. Any occurence of CGvHD (McNemar test) and
growth data (paired T-test) were analyzed at 1y and latest follow-
up available.
Results:MAmatches were found for 34/44 patients who received
a single RI HSCT. Mean age at first transplant was 9.45y for RI and
9.84y forMA (p5 0.15). 20/34 pairs (59%) were same gender. 24/34
pairs (71%) were matched for related/unrelated, and 17/34 pairs
(50%) agreed for both matched/unmatched and related/unrelated.
21/34 (62%) were matched for HSC source, all mismatches were
RI peripheral blood HSCs with MA bone marrow (n 5 12) or
cord blood (n 5 1). The length of follow-up to latest visit differed
between RI patients at mean 966 (range 462–2512) days and MA at
2025 (range 525–4538) days (p5 0.006). No differences seen in Ta-
ble 1 were significant, although 1 year height Z scores approached
significance with p 5 0.051.
Growth parameters and prevalence of CGvHD at specific
timepoints
RI MA RI MA1 year (n531) Latest F/U (n531)Extensive CGvHD 3/31 (10%) 6/31 (19%) 2/31 (6%) 1/31 (3%)
1 year (n515)1 Latest F/U (n510)1Height Z score –0.78 –0.14 –0.86 –0.47
BMI Z score 0.13 0.98 1.01 1.311Full growth parameters, especially height, were not available at all visits.
Conclusions: At specific follow-up timepoints, there was no dif-
ference in CGvHD prevalence or in growth parameters between
age- and diagnosis-matched RI and MA HSCT recipients. This
study did not allow survival curve analysis of CGvHD, as occurrence
was only assessed at specific timepoints. Height Z scores were less
than zero at all timepoints, indicating that growth is affected both
by RI andMA regimens. Longer follow-upwill be necessary to ascer-
tain if growth effects are different over time between RI and MA re-
cipients, and this study by design will also assess differences in late
effects such as endocrine or other organ system dysfunction.209
REDUCED INTENSITY CONDITIONING (RIC) IS ASSOCIATED WITH A SIG-
NIFICANT DECREASE IN DAY 1100 NON-RELAPSE MORTALITY (NRM),
GRADE II-IV AGVHD AND OVERALL SURVIVAL (OS) IN PEDIATRIC RECIP-
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We and others have demonstrated that myeloablative condition-
ing (MAC) and CBT results in a high engraftment rate and lower
severe AGVHD rate but a 20–40% incidence of Day 1100 NRM
(Cairo et al BBMT, 2008). RIC and AlloSCT in adults have been
associated with a decrease in acute toxicity and NRM (Satwani/
Cairo et al BBMT, 2005). Our group recently demonstrated the
safety and sustained high donor chimerism following RIC and
UCBT in pediatric recipients (Bradley/Cairo et al BMT, 2007).
In this study we investigated the risk factors associated with Day
1100 NRM, Grade II-IV AGVHD and OS in 101 consecutive
CBT pediatric recipients. Probability of Day 1100 NRM and OS
were calculated by Kaplan Meier estimates. Continuous variables
are summarized as mean 6 SD and categorical variables as %.
Risk factors for Grade II-IV AGVHD and Day1100 NRMwas as-
sessed by logistic regression and and OS was assessed by Cox pro-
portional hazards; variables \0.2 in univariate were included in
multivariate analyses. Risk factors: RIC vs MAC, average vs poor
risk, malignant/non, HLA 4/6 vs $4/6, CMV donor/recipient,
CD34\2.3 vs $2.3  105 CD34/kg, TNC 3, $3\5, $5  107
TNC/kg, Grade II-IV AGVHD, chronic GVHD. 101 pts, age
7.6 6 6.5 yrs; M/F 60/40%; MAC/RIC 55/45%; average/poor
risk 74/26%; CMV -/- 26%; HLA 4/6 52%; malignant/non 66/
34%. Median time to ANC and platelet recovery was similar be-
tween RIC and MAC CBT (24 vs 24) and (59 vs 64) d, respectively.
Day 180 and 365 chimerism was also similar (84 vs 89%) and (89 vs
92%), respectively. However, the probability of Grade II-IV
AGVHD was significantly less following RIC 20% (CI95 8.3%–
31.7%) vs 42.9% (CI95 29.9%–55.8%%) (p\ 0.015). Multivariate
analysis demonstrated the following independent risk factors in
Grade II-IV AGVHD: High CD34 hazard ratio (HR): 3.1,
p\0.02; HLA 4/6 HR: 4.2, p\0.007 and MAC HR: 4.1,
p\0.005. Day 1100 NRM was significantly less following RIC
2.3% (CI95 0–6.7%) vs. 26.1% (CI95 14.3%–37.8%), p\0.002.
The only significant factor in Day 1100 NRM was MAC HR:
27.2, p\0.005. Lastly, 3yr OS was significantly improved following
RIC 56% (CI95 37–70) vs MAC 28% (CI95 16–40) and the follow-
ing risk factors: Low vs High CD34 HR: 1.0 vs 0.38, p\0.004;
and MAC HR: 2.9, p\0.001 were associated with a significant
improvement in OS. In summary, RIC was the single most impor-
tant risk factor associated with a significant reduction in Grade II-
IV AGVHD, Day 100 NRM and OS in pediatric recipients
following CBT.210
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Background: Pediatric hematopoetic stem cell transplant
(HSCT) recipients requiring critical care services historically have
poor outcomes. There appears to be a wide range of clinical ap-
proaches to this patient population. Clinical trials utilizing evi-
denced-based protocols are needed to improve outcomes. A better
understanding of the variations in care of these patients is needed
to design future trials. The Pediatric Acute Lung Injury and Sepsis
Investigators (PALISI) Network surveyed the most active United
States pediatricHSCTprograms regarding the care provided to crit-
ically ill patients.
